Merck (MRK) is often reduced to one question: what happens when Keytruda eventually loses exclusivity. That debate is understandable, but the latest quarter shows why it is too narrow to describe the business investors own today. In Q1 2026, Merck reported worldwide sales of $16.3 billion, up 5% on a nominal basis and 3% excluding exchange, with management highlighting strength in oncology and animal health along with increasing contributions from newer launches (Merck Q1 2026 results materials, April 30, 2026). That mix points to a company still concentrated in an important franchise, but not one standing still.
Thesis and Why the Keytruda-Cliff Framing Is Too Narrow
The bearish shorthand on Merck is that Keytruda is so large that everything else is secondary. The problem with that framing is not that Keytruda is unimportant. It is that the rest of the portfolio is becoming more relevant at the same time. Merck’s Q1 2026 materials described a company “moving with speed” to build a more diversified set of growth drivers across therapeutic areas, and the quarter’s results support that direction rather than contradict it.
Related Coverage
Keytruda remains the anchor. Merck’s Keytruda family generated $8.0 billion in Q1 2026 sales, up 8% year over year, driven by continued demand in metastatic indications and additional uptake in earlier-stage settings (Merck Q1 2026 earnings presentation, April 30, 2026). But the right investor takeaway is not simply that Merck still depends on Keytruda. It is that Merck is using today’s oncology cash engine to extend its position, fund launches, and support newer growth vectors before the exclusivity debate becomes the whole story.
That distinction matters because valuation debates can flatten a transition into a cliff. Merck’s current earnings base is still being powered by a leading oncology franchise, yet the Q1 2026 release already showed other pillars growing in parallel. Investors who look only at the patent calendar risk missing how much of the next Merck is being built while the existing blockbuster still throws off scale.
How Oncology Breadth and New Launches Support the Growth Base
Oncology remains Merck’s main commercial advantage, but it is broader than a single mature product label implies. Keytruda continues to expand through indication depth, combination use, and ongoing regulatory progress. Merck said the FDA accepted four filings across its oncology portfolio in the quarter, including a new biologics filing for ifinatamab deruxtecan in small cell lung cancer. That matters because it shows the company still has multiple shots at reinforcing its cancer franchise rather than simply defending one brand.
The newer-launch contribution is also becoming more visible. Merck’s Q1 2026 materials said the quarter benefited from increasing contributions from launches, and one of the clearest examples was WINREVAIR. The product generated $525 million in Q1 2026 sales, driven by continued growth in new patient starts and total prescriptions (Merck Q1 2026 earnings presentation, April 30, 2026). WINREVAIR is not an oncology asset, but it is important to the investment case because it demonstrates Merck can still create meaningful new commercial engines outside its legacy blockbuster base.
This is the broader point: Merck does not need a single product to replace Keytruda dollar for dollar overnight for the stock thesis to work. It needs a portfolio in which oncology breadth, newer launches, and adjacent franchises together keep the earnings base from narrowing too quickly. Q1 2026 offered evidence that the transition is active rather than theoretical.
Why Animal Health and Commercial Diversification Matter to Durability
Animal Health is one of the clearest reasons Merck should not be viewed only through a human-pharma patent lens. The business delivered $1.8 billion in Q1 2026 sales, up 6% year over year, with growth driven by both livestock and companion animal products (Merck Q1 2026 earnings presentation, April 30, 2026). That segment is smaller than oncology, but it matters because it adds a steadier, less patent-binary source of revenue to the overall mix.
The same can be said for the shape of Merck’s broader commercial portfolio. Not every major business line moved perfectly in the quarter. Merck disclosed that Gardasil sales were $1.1 billion in Q1 2026, down 22%, driven by lower demand in China and Japan. That softness is a reminder that diversification does not mean every product will rise at once. What it does mean is that weakness in one area does not automatically define the whole company when oncology, animal health, and launches are still supporting the top line.
For long-term investors, durability comes from having several businesses that can matter at different times. Animal Health will not command the same headlines as Keytruda, but it gives Merck a commercial engine with different demand drivers, different competitive rhythms, and less dependence on a single patent cycle. In a company of Merck’s scale, that kind of diversification deserves more weight than it often gets in headline debates.
Investor Takeaway and What to Watch Across Growth Drivers, Concentration, and Pipeline Execution
The better lens for Merck is not “ignore Keytruda risk.” It is “measure whether Merck is broadening its earnings base fast enough while Keytruda remains strong.” Q1 2026 supports that framing. Worldwide sales still grew to $16.3 billion. Keytruda still expanded to $8.0 billion. Animal Health still grew to $1.8 billion. WINREVAIR is already a meaningful launch at $525 million in quarterly sales. Taken together, those figures describe a company with both concentration and diversification at the same time.
That does not make the patent-cliff issue disappear. Investors should keep watching how much of Merck’s growth is still tied to Keytruda, how quickly newer products scale, and whether pipeline milestones keep translating into approved uses and real revenue. The question is whether Merck looks like a one-franchise company waiting for decay or a multi-engine platform using one dominant franchise to finance the next phase of growth.
Right now, the evidence looks closer to the second version. Merck’s latest quarter showed that the transition away from a one-product narrative is already under way. For investors willing to look past the simplest bearish frame, that is the more durable part of the story.
Key Signals for Investors
Q1 2026 worldwide sales of $16.3 billion, up 5% nominally, show Merck is still growing even as investors focus on the eventual Keytruda exclusivity debate.
Keytruda family sales of $8.0 billion, up 12% year over year, mean the core oncology engine is still expanding rather than merely harvesting a mature franchise.
Animal Health sales of $1.8 billion, up 6%, are an important reminder that Merck has meaningful commercial diversification outside human oncology.
WINREVAIR’s $525 million in Q1 2026 sales suggest Merck can still build large new growth drivers before the patent discussion becomes more urgent.
Sources
Merck, Our Q1 2026 Financial Results, April 30, 2026. https://www.merck.com/stories/our-q1-2026-financial-results/
Merck, First Quarter 2026 Sales and Earnings Presentation, April 30, 2026. https://www.merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Earnings-Presentation.pdf
All figures cited above are from Merck primary-source materials for Q1 2026.
